

Supplementary Table S3

TCGA STUDY NAME	No. of cases altered	Total no. of cases	Percentage altered
Adrenocortical Carcinoma	9	90	10%
Bladder Urothelial Carcinoma	17	130	13.10%
Brain Lower Grade Glioma	5	286	1.70%
Breast Invasive Carcinoma	29	982	3%
Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma	16	194	8.20%
Cholangiocarcinoma	8	35	22.90%
Colorectal Adenocarcinoma	27	223	12.10%
Esophageal Carcinoma	28	185	15.10%
Glioblastoma Multiforme	13	290	4.50%
Head and Neck Squamous Cell Carcinoma	35	512	6.80%
Kidney Chromophobe	12	66	18.20%
Kidney Renal Clear Cell Carcinoma	26	451	5.80%
Kidney Renal Papillary Cell Carcinoma	12	282	4.30%
Liver Hepatocellular Carcinoma	20	373	5.40%
Lung Adenocarcinoma	26	230	11.30%
Lung Squamous Cell Carcinoma	18	177	10.20%
Lymphoid Neoplasm Diffuse Large B-cell Lymphoma	6	48	12.50%
Ovarian Serous Cystadenocarcinoma	10	316	3.20%
Pancreatic Adenocarcinoma	6	150	4%
Pheochromocytoma and Paraganglioma	6	184	3.30%
Prostate Adenocarcinoma	26	499	5.20%
Sarcoma	6	247	2.40%
Skin Cutaneous Melanoma	69	368	18.80%
Stomach Adenocarcinoma	58	395	14.70%
Testicular Germ Cell Cancer	15	155	9.70%
Thymoma	2	123	1.60%
Thyroid Carcinoma	3	405	0.70%
Uterine Carcinosarcoma	3	57	5.30%
Uterine Corpus Endometrial Carcinoma	35	248	14.10%
Uveal Melanoma	1	80	1.30%

average 8%

median 6%

range 0.7-22.9%

standard deviation 0.058968568